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Dear	editor,
Pemphigus is an autoimmune bullous disease that can af-
fect	the	skin	and	mucous	membranes,	mediated	by	autoantibodies	
against	 desmosomal	 desmogleins,	 the	 main	 adhesion	 structures	
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discrete	desquamation	and	more	severe	clinical	complaints	on	the	
feet	(Figure	1).	The	lesions	were	stationary	and	limited	to	the	palms	
and	feet.	The	patient	reported	no	other	drug	intake	or	allergic	back-
ground. No pruritus was reported.
Patient medication included Sorafenib at 400 mg twice dai-
ly,	started	6	weeks	prior	to	present	consultation.
The patient refused biopsy for histopathological evaluation.
We	 tried	 topical	 steroids	 and	urea	 10%	 cream	 to	 improve	
the	symptoms,	but	achieved	no	results	after	one	month	of	contin-
uous topical therapy. Despite the uncomfortable dermatological 
problems,	the	patient	was	advised	to	continue	with	sorafenib	che-
motherapy.
The list of sorafenib-related adverse reactions is long and 
gets even longer with new reports including hand-foot syndrome.4 
It	has	been	classified	into	3	grades	based	on	clinical	features:5
• Grade I: slight erythema and swelling with minimal dyses-
thesia;
• Grade II: pain is present along with other clinical changes 
and interferes with daily life;
• Grade III: blistering,	desquamation	and	even	ulceration	ac-
companied by extremely severe pain.
Although	 the	 exact	mechanism	of	 these	adverse	 reactions	
is	 still	 unclear,	 some	 possible	 explanations	 could	 be	 the	 pressure	
exerted	on	palms	and	feet	and	secondary	 increased	blood	flow	to	
these	areas.	Therefore,	the	side	effect	is	not	an	allergic	reaction	to	a	
culprit drug.
The present case is a typical grade 3 hand-foot syndrome re-
lated to sorafenib treatment for advanced hepatocellular carcinoma.
Skin	toxicity	related	to	sorafenib	has	a	great	impact	on	the	pa-
tients’	quality	of	life	and	represents	a	challenge	in	oncology	practice.	
Patient reassurance is crucial to avoid chemotherapy abandonment. q
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FIgure 1: Intense erythema on the right hand (a) and right foot 
(b) and	desquamation	on	the	right	foot	accompanied	by	invalidat-
ing pain
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between	keratinocytes.1 Many are the factors attributed to its devel-
opment,	but	drugs	are	 the	main	cause.1 Medications can cause or 
exacerbate pemphigus lesions.1 Drug-induced pemphigus lesions 
are histopathologically identical to those of idiopathic pemphigus 
vulgaris.2	Due	to	the	lack	of	reports	in	the	literature,	we	present	a	
case	of	biologic-induced	pemphigus,	in	a	patient	in	whom	the	med-
ication was being used to treat severe rheumatoid arthritis.
We	present	a	case	of	a	41-year	old	female	patient,	phototype	
II,	 that	 presented	 with	 cutaneous	 redness,	 peeling,	 and	 pruritus	
on	the	thoracic	region	in	the	past	15	days,	after	sun	exposure.	On	
physical	 examination,	 erythema	and	 telangiectasia	were	observed	
in	the	malar	regions	and	dorsum	of	nose,	along	with	papules	and	
erythematous,	scaly	plaques	on	the	neckline	(Figure	1).
The	 patient	 has	 had	 rheumatoid	 arthritis	 for	 10	 years,	 for	
which	she	was	using	methotrexate	and	prednisone	 (5	mg/day)	 for	
5	years,	secukinumab	for	3	months	and	paracetamol	as	needed.	She	
was	allergic	to	dipyrone.	The	patient	had	already	used	chloroquine	
diphosphate (discontinued more than 10 years ago due to retinal 
maculopathy),	etanercept	(between	2008	and	2010)	and	adalimumab	
(between	2011	and	2012,	both	discontinued	due	to	lack	of	clinical	re-
sponse).	Her	Family	history	included	mother	with	hyperthyroidism.
Serology	 revealed	 rheumatoid	 factor	 80	 UI/ml	 and	ANA	
with	 nuclear	 fine	 speckled	 pattern	 1:1.280.	 Other	 autoantibodies	
were negative. The histopathology showed focal area with su-
prabasal	 acantholysis	 involving	 the	 follicular	 epithelium,	 besides	
acanthosis	and	crust	with	fibrin	and	leukocytes	(Figure	2).	 Immu-
nohistochemistry	 for	 IgG	 and	 C3	was	 positive,	with	 intercellular	
distribution,	 corresponding	 to,	 along	with	 the	 clinical	history,	 the	
diagnosis	of	drug-induced	pemphigus	(Figure	2).
In	cooperation	with	rheumatology,	we	decided	to	discontin-
ue	secukinumab,	increase	the	dose	of	methotrexate	and	add	topical	
steroid,	 with	 gradual	 improvement	 of	 the	 lesions	within	 a	month	
(Figure	1).	Since	it	was	considered	a	relatively	mild	case,	with	rapid	
improvement,	and	since	the	patient	had	severe	rheumatoid	arthritis,	
with	deformities,	a	biologic	drug	was	reintroduced.	The	rheumatol-
ogists	opted	to	use	tocilizumab,	and	15	days	after	the	new	treatment,	
FIgure 1:  A) Erythematous	scaly	papules	and	plaques,	with	some	
superficial	ulcerations	on	the	neckline;	B) Improvement after treat-
ment.
FIgure 2:  A) Focal	area	with	suprabasal	acantholysis,	involving	the	
follicular	epithelium,	besides	acanthosis	and	crust	with	fibrin	and	
leukocytes	 (HE,	X100);	B) Immunohistochemistry with expression 
of intercellular IgG; C) Immunohistochemistry with expression of 
intercellular C3. 
the	patient	presented	with	the	same	lesions,	 this	time	with	vesicles	
of	approximately	5	mm	in	the	inframammary	region,	abdomen	and	
upper	limbs,	that	improved	after	discontinuing	the	medication	once	
again.	 Histopathology	 of	 the	 new	 lesions	 confirmed	 the	 previous	
diagnosis,	with	positive	direct	immunofluorescence	for	intercellular	
IgG	and	C3,	corroborating	the	diagnosis	of	drug-induced	pemphigus.	
The possibility of association of medications with new cases 
of	pemphigus	should	always	be	suspected,	since	many	cases	can	be	
caused	and	worsened	by	drugs,	in	special	penicillamine,	followed	
by	the	group	of	ACE	inhibitors.	The	time	gap	between	drug	expo-
sure	 and	 onset	 of	 skin	 lesions	 varies,	making	 the	 diagnosis	 even	
more	difficult	when	the	patient	uses	multiple	drugs	concomitantly.3
There are 3 groups of drugs with different chemical struc-
tures	involved	in	the	development	of	pemphigus.	The	thiol	group,	
to	which	penicillamine	belongs,	 includes	drugs	with	the	ability	to	
activate	proteolytic	 enzymes,	 to	 interfere	 in	 the	 enzyme	activities	
of	 the	 keratinocytes	 and	 to	 bind	 to	 desmoglein	 1	 and	 3,	 inciting	
the immune response or preventing their role in cellular adhesion. 
The	phenol	group,	that	includes	aspirin,	rifampicin	and	levodopa,	
causes	acantholysis,	participating	in	the	regulation	and	synthesis	of	
complement and proteases. The third group — nonthiol and non-
phenol	—	encompasses	other	drugs	that	take	a	part	in	the	acanthol-
ysis process via many mechanisms.1
Biologic	drugs,	such	as	the	ones	used	by	the	patient,	are	in	
the	 third	 group.	 Secukinumab,	 a	monoclonal	 antibody	 anti-IL-17	
and	tocilizumab,	a	IL-6	receptor	antagonist,	are	utilized	by	those	pa-
tients that are unresponsive to TNF-alfa antagonists.4	Secukinumab	
has	a	half-life	of	22	to	31	days,	tocilizumab’s	half-life	is	11	to	13	days	
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in adults.6	The	metabolism	of	both	drugs	is	still	unknown.5
Biologic drugs can trigger immediate transfusion reactions 
and rarely induce the formation of cellular autoantibodies or even 
autoimmune	 conditions,	 such	 as	 lupus	 erythematosus,	 usually	
of	 late	 onset.	The	 frequency	of	 tocilizumab’s	 infusion	 reactions	 is	
around	7%;	in	a	recent	study	with	226	infusions	in	individuals	with	
autoimmune	conditions,	no	immediate	infusion	reactions	were	ob-
served.	Nonetheless,	it	is	still	a	medication	with	limited	use.7
There are no reports of biologic drug-induced pemphigus 
until now. We highlight the importance of the dermatologist in the 
pharmacovigilance phase for new drugs. q
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Dear	Editor,
An	 80-year-old	 male	 presented	 with	 chronic	 non-healing	
ulcers involving the left side of the scalp and forehead for three 
months. The lesions were associated with intractable itching and 
vague	 crawling	 sensation.	 Following	 that,	 he	 started	picking	 and	
rubbing	 his	 skin,	 which	 resulted	 in	 ulcers.	 His	 medical	 history	
was	suggestive	of	herpes	zoster	involving	the	left	ophthalmic	(V1)	
branch of the trigeminal nerve for nine months. Physical examina-
tion revealed a 4x3-cm ulcer involving the left frontal aspect of the 
scalp	 and	 two	other	 small	 ulcers,	 one	 involving	 the	 center	 of	 the	
scalp	and	the	other	above	the	lateral	aspect	of	the	left	eyebrow,	cor-
responding	to	the	ophthalmic	(V1)	branch	of	the	trigeminal	nerve.	
The	latter	lesion	showed	areas	of	post	inflammatory	depigmentation	
(Figure	 1).	 Routine	 hematological	 and	 biochemical	 investigations	
were within normal limits. Head MRI revealed age-related cortical 
atrophy and was otherwise normal. Systemic examination revealed 
no	abnormality.	A	diagnosis	of	trigeminal	trophic	syndrome	(TTS)	
was	entertained.	The	patient	was	treated	with	occlusive	dressings,	
topical	antibiotics,	and	carbamazepine	with	complete	resolution	of	
the	lesions	within	three	weeks	(Figure	2).
TTS	is	a	rare	clinical	entity	characterized	by	unilateral	facial	
ulceration	 involving	 the	 trigeminal	 nerve	 (TN)	 territory	 following	
damage to its central or peripheral nerve structure. The classical clini-
cal	triad	of	TTS	consists	of	trigeminal	anaesthesia,	facial	paraesthesia,	
and crescent shaped ulcers.1 The presenting features will be that of 
picking,	rubbing,	or	scratching	sensations	on	the	affected	areas	sec-
ondary	to	hypoesthesia,	paraesthesia,	or	pain	resulting	from	damage	
of	 the	 sensory	 trigeminal	fibers.2 Adolf	Wallenberg	was	 the	first	 to	
describe TTS in 1895 in a patient with lateral medullary infarction.3
TTS	is	frequently	triggered	by	iatrogenic	causes,	usually	fol-
lowing procedures for pain management in trigeminal neuralgia.4 
Other	causes	include	stroke,	acoustic	neuroma,	post-infectious	en-
cephalitis,	 trauma,	 amyloid	deposits	 in	 the	TN,	 and	 infections.1,4,5 
Herpes	zoster	and	leprosy	are	also	major	dermatological	causes	for	
TTS.5
